Literature DB >> 22592660

MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome.

Anders Näsman1, Emilia Andersson, Cecilia Nordfors, Nathalie Grün, Hemming Johansson, Eva Munck-Wikland, Giuseppe Massucci, Tina Dalianis, Torbjörn Ramqvist.   

Abstract

Human papillomavirus (HPV) is an important factor for the development of tonsillar squamous cell carcinoma (TSCC). In addition, patients with HPV-positive TSCC have a better clinical outcome than patients with HPV-negative TSCC. Although, HPV is an important prognostic marker, additional biomarkers are needed to better predict clinical outcome to individualize treatment. Hence, we examined if classical HLA HLA-A,B,C and nonclassical HLA-E,G could serve as such marker. Formalin-fixed paraffin-embedded TSCC from 150 patients diagnosed 2000-2006, earlier analyzed for HPV DNA and p16(INK4a), and treated with intention to cure were evaluated for the expression of HLA-A,B,C and HLA-E,G by immunohistochemistry. For HPV-positive TSCC a low expression of HLA-A,B,C, whereas for HPV-negative TSCC, a normal expression of HLA-A,B,C was significantly correlated to a favorable clinical outcome. These correlations were more pronounced for membrane staining of HLA-A,B,C when compared with cytoplasmatic staining. No significant correlation was found between HLA-E,G and HPV status or clinical outcome. The unexpected contrasting correlation between HLA-A,B,C expression, and clinical outcome depending on HPV, indicates essential differences between HPV-positive and HPV-negative TSCC. Furthermore, our data demonstrate that for both HPV-positive and HPV-negative TSCC, the expression of HLA-A,B,C together with HPV may serve as a useful biomarker for predicting clinical outcome.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592660     DOI: 10.1002/ijc.27635

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.

Authors:  Bin Xu; Achim A Jungbluth; Denise Frosina; Bayan Alzumaili; Nathaniel Aleynick; Elzbieta Slodkowska; Kevin Higgins; Alan Ho; Luc Morris; Ronald Ghossein; Nora Katabi
Journal:  Histopathology       Date:  2019-10-02       Impact factor: 5.087

2.  HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

Authors:  Bianca Cioni; Ekaterina S Jordanova; Erik Hooijberg; Rianne van der Linden; Renee X de Menezes; Katherine Tan; Stefan Willems; Joris B W Elbers; Annegien Broeks; Andries M Bergman; Charlotte L Zuur; Jan Paul de Boer
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

Review 3.  Going back to class I: MHC and immunotherapies for childhood cancer.

Authors:  Kellie B Haworth; Jennifer L Leddon; Chun-Yu Chen; Edwin M Horwitz; Crystal L Mackall; Timothy P Cripe
Journal:  Pediatr Blood Cancer       Date:  2014-12-18       Impact factor: 3.167

Review 4.  P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects.

Authors:  Hongzhi Wang; Rui Sun; Hui Lin; Wei-Han Hu
Journal:  Cancer Sci       Date:  2013-11-08       Impact factor: 6.716

5.  Absent/weak CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival.

Authors:  Anders Näsman; Cecilia Nordfors; Nathalie Grün; Eva Munck-Wikland; Torbjörn Ramqvist; Linda Marklund; David Lindquist; Tina Dalianis
Journal:  Cancer Med       Date:  2013-06-14       Impact factor: 4.452

6.  Correlation of LMP10 expression and clinical outcome in Human Papillomavirus (HPV) positive and HPV-Negative tonsillar and base of tongue cancer.

Authors:  Nikolaos Tertipis; Linnea Haeggblom; Cecilia Nordfors; Nathalie Grün; Anders Näsman; Andrea Vlastos; Tina Dalianis; Torbjörn Ramqvist
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

7.  Expression of EPHRIN-A1, SCINDERIN and MHC class I molecules in head and neck cancers and relationship with the prognostic value of intratumoral CD8+ T cells.

Authors:  Meriem Hasmim; Cécile Badoual; Philippe Vielh; Françoise Drusch; Virginie Marty; Agnès Laplanche; Mariana de Oliveira Diniz; Hélène Roussel; Eléonore De Guillebon; Stéphane Oudard; Stéphane Hans; Eric Tartour; Salem Chouaib
Journal:  BMC Cancer       Date:  2013-12-11       Impact factor: 4.430

8.  Immunotherapy of HPV-associated head and neck cancer: Critical parameters.

Authors:  Mevyn Nizard; Federico Sandoval; Cecile Badoual; Helene Pere; Magali Terme; Stephane Hans; Nadine Benhamouda; Clemence Granier; Daniel Brasnu; Eric Tartour
Journal:  Oncoimmunology       Date:  2013-04-16       Impact factor: 8.110

9.  HLA class I and II expression in oropharyngeal squamous cell carcinoma in relation to tumor HPV status and clinical outcome.

Authors:  Anders Näsman; Emilia Andersson; Linda Marklund; Nikolaos Tertipis; Lalle Hammarstedt-Nordenvall; Per Attner; Tommy Nyberg; Giuseppe V Masucci; Eva Munck-Wikland; Torbjörn Ramqvist; Tina Dalianis
Journal:  PLoS One       Date:  2013-10-10       Impact factor: 3.240

10.  Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations.

Authors:  Stefan Holzhauser; Nicole Wild; Mark Zupancic; Ramona G Ursu; Cinzia Bersani; Anders Näsman; Ourania N Kostopoulou; Tina Dalianis
Journal:  Front Oncol       Date:  2021-05-11       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.